Lupin has reported results for first quarter ended June 30, 2014.
The company has posted over two fold jump in its net profit to Rs 1016.73 crore as compared to Rs 410.55 crore for the quarter ended June 30, 2013. Its total income has increased by 52.54% to Rs 3025.55 crore for the quarter under review from Rs 1983.32 crore for the corresponding quarter of the previous year.
On the consolidated basis,the company’s net profit from ordinary activities after tax for the quarter surged 55.77% at Rs 624.74 crore as compared to Rs 401.06 crore for the quarter ended June 30, 2013. Its total income has increased by 30.75% to Rs 3369.73 crore for the quarter under review from Rs 2577.11 crore for the corresponding quarter of the previous year.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.70 |
| Dr. Reddys Labs. | 1356.85 |
| Cipla | 1465.15 |
| Zydus Lifesciences | 1112.20 |
| Lupin | 2420.15 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: